Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 2 November 2026.
Announcements
1,179
Total raised
£24.7B
disclosed amounts
This month
£9.0M
raised so far
The Bath-based analytics firm has closed its latest round at £1.5m to support product development.
"We are delighted to close our Series A investment round at £1.5m. We had consistent advice early on – ‘it will take a ton of time, be prepared’, they were right!"
The investment was led by the Foresight Williams Technology EIS Fund and includes participation from existing shareholders as part of a £5m total raise.
"We are extremely pleased to welcome Foresight Group and Williams Advanced Engineering as new shareholders in our company. Bringing a major private equity investor alongside a world-renowned engineering company will be of extraordinary benefit to Rovco. We look forward to working with each of them as we expand the business and continue our success into 2020!"
Deepbridge Capital provides follow-on funding to accelerate preclinical pipelines and targeted therapies.
"We are delighted that Deepbridge has continued to support our future development."
Vickers Venture Partners led the Series A round to support clinical trials for set-point vaccines.
"Attracting such high calibre investors is an endorsement of our development pipeline and validation of the potential our technologies hold in the field of infectious diseases. These new funds will support us to achieve some significant value-enhancing milestones as we progress our lead vaccine candidates into clinical development."
The investment from BGF will support the rollout of the metra liver preservation system in the United States.
"This investment is key for 2 reasons. First, the funding will be critical in allowing us to execute our commercial plans in the US. Secondly, having BGF at the board table will ensure we leverage its impressive track record of successfully guiding growing businesses to achieve their full potential. Ultimately this is great news for all our stakeholders including current investors, employees and patients requiring a lifesaving organ transplant."
